Search

Your search keyword '"Vittecoq, Olivier"' showing total 710 results

Search Constraints

Start Over You searched for: Author "Vittecoq, Olivier" Remove constraint Author: "Vittecoq, Olivier"
710 results on '"Vittecoq, Olivier"'

Search Results

151. Abnormalities in the Biological or Haematological Domain of the Essdai Predict an Increase in Systemic Disease Activity the Year after: 5-Year Data from the Prospective Multicenter Assess Cohort

154. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry

156. Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry

159. Reply to the comment of Brinster et al. 'Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists'

160. Additional file 1: Table S1. of Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

161. Blood and livery gland BAF-driven B-cell hyperactivity in rituximab non responder patients with primary Sjögren's syndrome

163. Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response

164. Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?

165. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

166. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept:Results from the APPRAISE study

167. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate:results from the APPRAISE study

168. Method of treating rheumatoid arthritis

173. Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes

174. High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren’s Syndrome: Data from the TEARS Randomized Trial

176. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study

177. Soluble alpha-enolase activates monocytes by CD14-dependent TLR4 signalling pathway and exhibits a dual function

178. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome

179. B-cell and T-cell quantification in minor salivary glands in primary Sjögren’s syndrome: development and validation of a pixel-based digital procedure

180. Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

181. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients

182. Outcome of anti-PL12 positive patients with antisynthetase syndrome.[Profil évolutif du syndrome des antisynthétases avec anticorps anti-PL12]

183. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study

186. Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren’s Syndrome?

187. Prophylactic Injection of Recombinant Alpha-Enolase Reduces Arthritis Severity in the Collagen-Induced Arthritis Mice Model

189. Arthritis due to metastasis

190. Une arthrite métastatique

192. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylartropathy patients

193. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction

194. [Proteomics and autoantibody]

195. Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis

198. Biologic targeted therapies in pediatric rheumatology

199. No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis

Catalog

Books, media, physical & digital resources